BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 22879080)

  • 1. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis.
    Sobic-Saranovic D; Grozdic I; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko V; Saranovic D; Djuric-Stefanovic A; Masulovic D; Odalovic S; Ilic-Dudvarski A; Popevic S; Pavlovic S; Obradovic V
    J Nucl Med; 2012 Oct; 53(10):1543-9. PubMed ID: 22879080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis.
    Sobic-Saranovic DP; Grozdic IT; Videnovic-Ivanov J; Vucinic-Mihailovic V; Artiko VM; Saranovic DZ; Pavlovic SV; Obradovic VB
    Clin Nucl Med; 2013 Jul; 38(7):516-21. PubMed ID: 23486337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammatory activity assessment by F18 FDG-PET/CT in persistent symptomatic sarcoidosis.
    Mostard RL; Vöö S; van Kroonenburgh MJ; Verschakelen JA; Wijnen PA; Nelemans PJ; Erckens RJ; Drent M
    Respir Med; 2011 Dec; 105(12):1917-24. PubMed ID: 21899998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (18)F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: results of a preliminary prospective study.
    Ambrosini V; Zompatori M; Fasano L; Nanni C; Nava S; Rubello D; Fanti S
    Clin Nucl Med; 2013 Apr; 38(4):e171-7. PubMed ID: 23429384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
    Kauhanen S; Schalin-Jäntti C; Seppänen M; Kajander S; Virtanen S; Schildt J; Lisinen I; Ahonen A; Heiskanen I; Väisänen M; Arola J; Korsoff P; Ebeling T; Sane T; Minn H; Välimäki MJ; Nuutila P
    J Nucl Med; 2011 Dec; 52(12):1855-63. PubMed ID: 22052128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
    Keijsers RG; Verzijlbergen FJ; Oyen WJ; van den Bosch JM; Ruven HJ; van Velzen-Blad H; Grutters JC
    Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1131-7. PubMed ID: 19259660
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Chauvelot P; Skanjeti A; Jamilloux Y; de Parisot A; Broussolle C; Denis P; Ramackers JM; Giammarile F; Kodjikian L; Seve P
    Br J Ophthalmol; 2019 Nov; 103(11):1650-1655. PubMed ID: 30658987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular sarcoidosis: does (18)F-FDG PET/CT have any role?
    Jung RS; Mittal BR; Maturu NV; Kumar R; Bhattacharya A; Gupta D
    Clin Nucl Med; 2014 May; 39(5):464-6. PubMed ID: 24662648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
    Qiu ZL; Xue YL; Song HJ; Luo QY
    Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
    Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
    J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of (18)F-FDG PET/CT in inflammation of unknown origin.
    Balink H; Bennink RJ; Veeger NJ; van Eck-Smit BL; Verberne HJ
    Clin Nucl Med; 2014 May; 39(5):419-25. PubMed ID: 24662652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDG PET imaging in sarcoidosis.
    Sobic-Saranovic D; Artiko V; Obradovic V
    Semin Nucl Med; 2013 Nov; 43(6):404-11. PubMed ID: 24094707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis.
    Okumura W; Iwasaki T; Toyama T; Iso T; Arai M; Oriuchi N; Endo K; Yokoyama T; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Dec; 45(12):1989-98. PubMed ID: 15585472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid Imaging in Evaluation of Abdominal Sarcoidosis.
    Milojevic IG; Sobic-Saranovic D; Petrovic N; Beatovic S; Tadic M; Artiko VM
    Curr Med Imaging Rev; 2019; 15(1):26-31. PubMed ID: 31964324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ¹⁸F-FDG PET/CT for Therapy Control in Vascular Graft Infections: A First Feasibility Study.
    Husmann L; Sah BR; Scherrer A; Burger IA; Stolzmann P; Weber R; Rancic Z; Mayer D; Hasse B;
    J Nucl Med; 2015 Jul; 56(7):1024-9. PubMed ID: 25977463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET/CT in bone sarcoidosis.
    Grozdic Milojevic I; Sobic-Saranovic D; Videnovic-Ivanov J; Saranovic D; Odalovic S; Artiko V
    Sarcoidosis Vasc Diffuse Lung Dis; 2016 Mar; 33(1):66-74. PubMed ID: 27055838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E; Soydal C; Kucuk ON; Ibis E; Erbay G
    Nucl Med Commun; 2011 Dec; 32(12):1162-8. PubMed ID: 21946617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
    Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
    Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.